NasdaqGS:BMRNBiotechs
BioMarin Pharmaceutical (BMRN) Posts Phase 3 Win And FDA Filing In Hypochondroplasia
BioMarin Pharmaceutical (NasdaqGS:BMRN) reported positive Phase 3 VOXZOGO results in children with hypochondroplasia, published in NEJM Evidence.
The company filed a supplemental application with the FDA to expand VOXZOGO’s label as a targeted therapy for hypochondroplasia.
VOXZOGO is positioned as a potential first approved treatment for hypochondroplasia, building on its existing indication in achondroplasia.
The new VOXZOGO hypochondroplasia data and FDA filing come alongside broader...